OSAHS患者经羧甲司坦联合氨茶碱治疗的疗效及临床应用价值

摘要/Abstract

摘要： 目的：观察羧甲司坦联合氨茶碱对阻塞性睡眠呼吸暂停低通气综合征（OSAHS）患者睡眠质量及血清氧化应激指标的影响。方法：选取2021年1月至2023年5月本院收治的100例OSAHS患者为研究对象，采用奇偶数分组法分为对照组50例、联合组50例。对照组予以氨茶碱治疗，联合组予以羧甲司坦联合氨茶碱治疗。统计对比两组临床疗效及治疗前后呼吸调节指标、睡眠状态[睡眠转换次数、Epworth睡眠（ESS）评分、呼吸暂停低通气指数（AHI）、动脉血氧饱和度（SaO2）]、氧化应激[8-羟基脱氧鸟苷（8-OHG）、氧化型低密度脂蛋白（ox-LDL）、超氧化物歧化酶（SOD）、丙二醛（MDA）]、炎症因子[白细胞介素-6（IL-6）、超敏C反应蛋白（hs-CRP）、肿瘤坏死因子-α（TNF-α）]。结果：联合组总有效率为92.00%，高于对照组的76.00%，差异有统计学意义（P<0.05）；治疗后，联合组呼吸暂停低通气次数、最长呼吸暂停时间、最长呼吸低通气时间低于对照组，差异有统计学意义（P<0.05）；治疗后，联合组睡眠转换次数、ESS评分、AHI分别为（96.32±26.31）次、（6.52±1.85）分、（9.02±2.03）次/h，均低于对照组的（158.94±32.98）次、（9.54±2.18）分、（13.57±3.52）次/h，且SaO2（96.85±18.83%）高于对照组（88.20±19.41%），差异有统计学意义（P<0.05）；联合组治疗后血清8-OHG、ox-LDL、MDA水平低于对照组，SOD水平高于对照组，差异有统计学意义（P<0.05）；联合组治疗后血清IL-6、hs-CRP、TNF-α水平低于对照组，差异有统计学意义（P<0.05）。结论：羧甲司坦联合氨茶碱治疗OSAHS的疗效确切，可改善呼吸调节功能、睡眠质量，抑制炎症-氧化应激反应。

关键词: font-size:medium, ">阻塞性睡眠呼吸暂停低通气综合征；羧甲司坦；氨茶碱；睡眠质量；氧化应激

Abstract: Objective： To observe the effects of carboxymesteine combined with aminophylline on sleep quality and serum oxidative stress indexes in patients with obstructive sleep apnea hypopnea syndrome (OSAHS). Methods： A total of 100 OSAHS patients admitted to our hospital from January 2021 to May 2023 were selected as the study objects， and were divided into single group (50 cases) and combined group (50 cases) by odd-even grouping method. The single group was treated with aminophylline， and the combined group was treated with carboxymesteine combined with aminophylline. The clinical efficacy and respiratory regulation indexes， sleep status [Number of sleep transitions， Epworth sleep (ESS) score， apnea hypoventilation index (AHI)， arterial oxygen saturation (SaO2)].， oxidative stress [8-hydroxydeoxyguanosine (8-OHG)， oxidized low-density lipoprotein (ox-LDL)， superoxide dismutase (SOD)， malondialdehyde (MDA)]， and inflammatory factors [Interleukin-6 (IL-6)， hypersensitive C-reactive protein (hs-CRP)， tumor necrosis factor-α (TNF-α)] before and after treatment were statistically compared between the two groups. Results： The total effective rate of the combined group was 92.00%， which was higher than that of the single group (76.00%)， and the difference was statistically significant (P<0.05). After treatment， the number of apnea-hypopnea events， the longest apnea time， and the longest hypopnea time in the combined group were lower than those in the single group， and the differences were statistically significant (P<0.05). After treatment， the number of sleep transitions， ESS scores， and AHI in the combined group were (96.32±26.31) times， (6.52±1.85) scores， and (9.02±2.03) times/h， respectively， which were lower than those in the single group (158.94±32.98) times， (9.54±2.18) scores， and (13.57±3.52) times/h， and SaO2 (96.85±18.83%) was higher than that in the single group (88.20±19.41%)， and the differences were statistically significant (P<0.05). The levels of serum 8-OHG， ox-LDL， and MDA in the combined group were lower than those in the single group， and the level of SOD was higher than that in the single group， and the differences were statistically significant (P<0.05). The levels of serum IL-6， hs-CRP， and TNF-α in the combined group were lower than those in the single group， and the differences were statistically significant (P<0.05). Conclusion： The efficacy of Carbocisteine combined with Aminophylline in the treatment of OSAHS is confirmed， which can improve respiratory regulation function， sleep quality， and inhibit inflammation-oxidative stress response.

Key words: font-size:medium, ">Obstructive sleep apnea hypopnea syndrome； Carbomesteine； Aminophylline； Sleep quality； Oxidative stress

中图分类号:

王慧, 苑小倩, 梁耀升. OSAHS患者经羧甲司坦联合氨茶碱治疗的疗效及临床应用价值[J]. 中国药物评价, 2025, 42(1): 68-72.

WANG Hui, YUAN Xiaoqian, LIANG Yaosheng. The Therapeutic Efficacy and Clinical Application Value of Combining Carbocisteine with Aminophylline in Treating Patients with OSAHS[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2025, 42(1): 68-72.

参考文献

[1]李斌，严桂珍.严桂珍自拟“鼾症一号方”治疗阻塞性睡眠呼吸暂停低通气综合征经验[J]. 中华中医药杂志，2021，36(1)：214-216.
     [2]李静，林忠贤，周国红.氨茶碱联合布地奈德福莫特罗对AECOPD患者氧化应激及肺功能的影响[J]. 海南医学，2020，31(2)：167-170.
     [3]张映红，马兰.对比氨茶碱与枸橼酸咖啡因治疗呼吸暂停新生儿对其神经行为和后期神经发育的影响[J]. 贵州医药，2021，45(8)：1241-1243.
     [4]薛世民，高晓嵘，叶瑜，等.特布他林联合羧甲司坦片治疗慢性阻塞性肺疾病的疗效及对血清MMP-9、MMP-12、TIMP-1的影响[J]. 现代生物医学进展，2020，20(3)：532-535.
     [5]阻塞性睡眠呼吸暂停低通气综合征诊治指南(基层版)写作.阻塞性睡眠呼吸暂停低通气综合征诊治指南(基层版) [J]. 中华全科医师杂志，2015，14(7)：509-515.
     [6]陈清丹，陈沁，陈珺滢.从三焦气化失司论阻塞性睡眠呼吸暂停低通气综合征合并冠心病中医病机[J]. 中华中医药杂志，2019，34(7)：2932-2934.
     [7]彭莉莉，李进让，孙建军，等.Epworth嗜睡量表简体中文版信度和效度评价[J]. 中华耳鼻咽喉头颈外科杂志，2011，46(1)：44-49.
     [8]荆纯祥，冯毅翀，李际强，等.八段锦联合持续气道正压通气治疗老年阻塞性睡眠呼吸暂停低通气综合征的临床研究[J]. 中华中医药杂志，2021，36(11)：6904-6907.
     [9]Jiang YM， Peng JX， Song L. An OSAHS evaluation method based on multi-features acoustic analysis of snoring sounds[J]. Sleep Med， 2021， 84(1)：317-323.
     [10]张磊，孙岩，孙建伟，等.枸橼酸咖啡因注射液与氨茶碱注射液治疗低体重呼吸暂停早产儿的临床研究[J]. 中国临床药理学杂志，2021，37(7)：816-819.
     [11]吴保民，孙波.羧甲司坦治疗老年慢性阻塞性肺疾病急性加重期的疗效及对血清IL-8、TNF-α和IgE水平的影响[J]. 现代药物与临床，2021，36(3)：571-576.
     [12]汪娟，靳攀.沙丁胺醇气雾剂联合羧甲司坦片治疗AECOPD患者的临床效果[J]. 湖南师范大学学报（医学版），2022，19(3)：13-16.
     [13]梁丽，陀子能，周荣梅.氨茶碱与喷托维林对老年阻塞性睡眠呼吸暂停低通气综合征的治疗效果及安全性分析[J]. 黑龙江医学，2020，44(2)：244-245.
     [14]张毅，刘魏，靳传林.羧甲司坦片联合持续气道正压通气治疗老年阻塞性睡眠呼吸暂停低通气综合征患者的临床研究[J]. 中国临床药理学杂志， 2020， 36(11)：1427-1429.
     [15]康晓燕，朱君娜.经皮下电刺激技术联合他汀类药物治疗对肥胖型阻塞性睡眠呼吸暂停综合征患者脂代谢和氧化应激反应的影响[J]. 临床内科杂志，2020，37(4)：260-263.
     [16]ZHANG XF， RUI LJ， LV BL， et al. Adiponectin Relieves Human Adult Cardiac Myocytes Injury Induced by Intermittent Hypoxia[J]. Med Sci Monit， 2019， 25(1)：786-793.
     [17]OZBILGIC T， SUSLU AE， AYKAN HH， et al. The impact of the Adenotonsillectomy on cardiac functions and oxidative stress[J]. Int J Pediatr Otorhinolaryngol， 2022， 154(1)：111039-111049.
     [18]韩佳丽.羧甲司坦抗氧化治疗阻塞性睡眠呼吸暂停综合征的效果分析[J]. 中国实用医药，2022，17(2)：167-169.
     [19]邓利君，高蓉，李露，等.新型揿针治疗阻塞性睡眠呼吸暂停低通气综合征疗效及对相关炎性因子水平的影响[J]. 辽宁中医杂志，2024，51(3)：177-180.
     [20]李艳华，袁开芬，曹丽娇，等.阻塞性睡眠呼吸暂停低通气综合征合并慢性阻塞性肺疾病患者的心肺功能、缺氧程度及炎症因子变化的临床意义[J]. 中国呼吸与危重监护杂志，2022，21(9)：629-635.